Ibuprom Sprint Caps

Quick links

Choose a section

Quick links to important sections

Advertisements

Ibuprom Sprint Caps

Selected form

Advertisements

Overview of Ibuprom Sprint Caps

This section provides a foundational overview of Ibuprom Sprint Caps, defining its core identity, composition, classification, and general function, while highlighting its specialized formulation.

Property Description
Active ingredient Ibuprofen
Form Soft capsule (Liquid capsule)
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General purpose Symptomatic relief of pain and fever, reduction of inflammation
Origin Synthetic compound

Identity and Pharmacological Classification

Ibuprom Sprint Caps is an Over-The-Counter (OTC) medicinal product whose single active ingredient is Ibuprofen, a synthetic compound derived from propionic acid. The product is formally classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), a key pharmacological group for managing pain and inflammation.

This classification establishes the medicine’s general purpose, which is the symptomatic relief of discomfort through three linked actions: providing pain relief (analgesic), reducing inflammation (anti-inflammatory), and having an antipyretic (fever-lowering) effect. The efficacy of Ibuprofen as an analgesic agent is clinically recognized for its utility in controlling common symptoms.


Composition and Fast-Acting Formulation

The differentiating factor of the brand, "Sprint Caps," refers to its unique dosage form, the specialized soft capsule (or liquid capsule), designed for oral administration. Unlike conventional solid tablets, the active Ibuprofen is pre-solubilized within a liquid fill matrix encased by a gelatin shell.

This rapid-release design is fundamental to the product, as it enhances the speed of absorption into the bloodstream. This property of the soft capsule is engineered to deliver a quicker onset of action compared to traditional solid tablets, a characteristic of liquid-fill NSAID formulations. The medicine’s mechanism involves impeding the body's synthesis of prostaglandins, the chemical compounds responsible for initiating pain and swelling signals.

Regulatory References

  1. Ibuprofen: MedlinePlus Drug Information
Advertisements

What side effects are possible with Ibuprom Sprint Caps?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety restrictions for the active ingredient, Ibuprofen, based on authoritative governmental regulatory sources.


Serious Adverse Reactions and Safety Risks

The most serious regulatory concerns involve the Gastrointestinal (GI) and Cardiovascular (CV) systems. Official warnings cite the risk of GI bleeding, ulceration, or perforation, which can be fatal. There is also an increased risk of arterial thrombotic events, such as myocardial infarction (heart attack) and stroke, especially with higher doses and long-term use. Rare but severe hypersensitivity reactions (including anaphylaxis) and severe skin reactions (like Stevens-Johnson syndrome) are also documented.

Frequency-Classified and Common Reactions

Classification Examples of Reactions
Common Gastrointestinal disturbances (e.g., dyspepsia, nausea, vomiting, stomach pain, diarrhea).
Very Rare Severe cutaneous adverse reactions (SCARs), Aseptic Meningitis.

Population-Specific Restrictions

The medicine is strictly contraindicated during the last trimester of pregnancy. It must be used with particular caution in the elderly, who face an increased risk of serious adverse reactions, particularly GI bleeding and renal impairment. Use is also contraindicated in individuals with severe heart failure, severe renal failure, or active recurrent peptic ulcers.

Usage Limitations

Official documents mandate using the lowest effective dose for the shortest duration possible to minimize the potential for serious CV and GI risks. Concomitant use with other non-steroidal anti-inflammatory drugs (NSAIDs) should be avoided. Treatment must be discontinued immediately if signs of bleeding, ulceration, or a severe skin reaction occur.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The following information details the documented clinical and emergency considerations for overdose, based on official regulatory prescribing information for products containing ibuprofen.


Documented Overdose Manifestations

System Common Overdose Symptoms Serious/Severe Outcomes
Gastrointestinal Nausea, vomiting, abdominal pain Gastrointestinal bleeding or perforation
Central Nervous System Headache, ringing in the ears (tinnitus), blurred vision Confusion, decreased level of consciousness, seizures, coma
Renal/Metabolic Acute renal failure, metabolic acidosis

Urgent Action and When to Seek Help

Official regulatory documents emphasize that immediate medical attention is required if an individual has taken more than the maximum recommended dose, even if they appear well or are asymptomatic.

Emergency medical assistance should be sought immediately upon the onset of severe symptoms, including seizures, significant difficulty breathing, loss of consciousness, or signs of cardiovascular events such as chest pain or sudden weakness. Toxic effects are generally considered minor at doses below 100 mg/kg but may become severe at doses exceeding 400 mg/kg (referring to the active substance, ibuprofen).

Management of overdose is primarily supportive and symptomatic, with specific measures (e.g., gastric emptying, activated charcoal) considered in large, severe ingestions as determined by a healthcare provider.

Advertisements

Therapeutic Uses of Ibuprom Sprint Caps

What Ibuprom Sprint Caps Treats: Main Uses and Benefits

The primary role of Ibuprom Sprint Caps is to provide support that may assist with speedier symptomatic relief across therapeutic domains where symptoms related to physical discomfort, inflammation, or systemic imbalance are noticeable. The fast-acting liquid capsule formulation is generally considered relevant when temporary assistance for symptom management is appropriate.

The active ingredient is used to temporarily relieve minor aches and pains and reduce fever.

The medication is applied in clinical settings that involve acute or unstable symptom patterns, helping to address symptom clusters that may become intense or disruptive. It is commonly used to help with pain conditions such as typical headaches, the localized discomfort of a toothache, generalized muscle pain, and the challenging cyclical discomfort of primary dysmenorrhea (menstrual pain). This may assist with easing the overall symptom load during periods of heightened symptoms.

“The medicine is intended to offer symptomatic relief that may help patients cope more steadily with sudden episodes of pain and fever.”

Quick Fact: Relief for Acute Discomfort

Ibuprom Sprint Caps is relevant in contexts marked by increased discomfort associated with heightened physiological activity, such as the elevation of body temperature (fever) and the localized manifestations of swelling, tenderness, and stiffness associated with inflammatory states (e.g., following minor strains or during common illnesses). Often used when symptoms intensify and supportive relief is needed, this medicine assists with maintaining functional stability when symptoms interfere with routine activities.

Advertisements

Eligibility and Restrictions for Use

Ibuprom Sprint Caps are generally indicated for the short-term symptomatic treatment of mild to moderate pain (such as headache, migraine, toothache, muscle pain, and menstrual pain) and fever in adults and adolescents over 12 years of age.


Contraindications (Who Cannot Use)

This medication contains ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), and should not be used by individuals with the following conditions:

  • Hypersensitivity or allergic reactions (such as asthma, rhinitis, or hives) to ibuprofen, aspirin, or other NSAIDs.
  • Active or history of recurrent peptic ulcers (stomach/duodenal ulcers), gastrointestinal bleeding, or perforation, especially if related to previous NSAID therapy.
  • Severe heart failure (NYHA Class IV), severe liver failure, or severe kidney failure.
  • The third trimester of pregnancy.
  • Children under 12 years of age or adolescents weighing less than 40 kg.
  • Cerebrovascular or other active bleeding.
  • Concurrent use with other NSAIDs (including COX-2 inhibitors) or pain-relieving doses of acetylsalicylic acid.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory authorities classify the interactions of Ibuprom Sprint Caps (Ibuprofen) based on the risk of additive adverse effects or changes in drug concentration. The profile is structured around prohibiting specific high-risk combinations and requiring caution with others.


Officially Documented Contraindicated Combinations

Combinations explicitly prohibited to minimize safety risks include:

  • Other NSAIDs: Including other ibuprofen products, high-dose aspirin, and COX-2 specific inhibitors, due to a significantly increased risk of gastrointestinal bleeding.
  • Peri-operative pain in CABG surgery: Use is prohibited due to the increased risk of serious cardiovascular events.
  • Third Trimester of Pregnancy: Use is contraindicated due to potential fetal harm.

Significant Interaction Categories

Interacting Product Category Regulatory Concern (Official Description)
Anticoagulants (e.g., Warfarin) Increased risk of severe bleeding.
Lithium and Methotrexate Reduced renal clearance of the co-administered drug, leading to increased plasma concentration.
Antihypertensives (e.g., ACE Inhibitors) Reduced effectiveness of the blood pressure-lowering effect.
Low-Dose Aspirin (for antiplatelet effect) Interference with the antiplatelet action.
Alcohol Increased risk of stomach bleeding and central nervous system effects.

Caution is also noted for Elderly Patients due to a higher risk of interaction-related stomach bleeding, and specific timing is required when co-administering with low-dose Aspirin to preserve its cardioprotective effect.

Advertisements

Mechanism of Action

How Ibuprom Sprint Caps Works: Biological Mechanism


Modulation of the Prostanoid System

This core action is defined by the drug's role as a non-selective, reversible inhibitor of the Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. Inhibition of these enzymes blocks the conversion of arachidonic acid into prostaglandins and other prostanoids, which are key chemical signaling mediators. This initial molecular step is vital for the resulting system-level modulation.


Downstream Physiological Consequences

The reduced synthesis of prostaglandins affects two main physiological systems. Peripherally, it results in the decreased sensitization of nociceptors, as the chemical mediators that lower the pain receptor firing threshold are limited. Centrally, the inhibition of prostaglandin E2 ( PGE2) synthesis within the hypothalamus prevents the elevation of the body's thermoregulatory set point, leading to the modulation of the hypothalamic thermoregulatory set point during fever states.

Advertisements

Dosage and Administration Information

The use of Ibuprom Sprint Caps (ibuprofen 200 mg soft capsules) is governed by specific instructions to ensure standardized and correct administration. Adherence to these guidelines is mandatory.

Official Administration Guidelines

Administration Scope Instruction
Route Oral (swallow the soft capsule with water)
Age/Weight Adults and adolescents at least 12 years of age (at least 40 kg body weight)
Dosing Amount 1 to 2 capsules (200 mg to 400 mg) as a single dose
Dosing Frequency The dose may be repeated every 4 hours as required.
Maximum Daily Dose 6 capsules (1200 mg) in any 24-hour period must not be exceeded.
Timing Relative to Food Take after meals. It is recommended that patients with a sensitive stomach take the medicine during a meal.
Duration of Use For short-term use only. Do not use for more than 3 days for fever or 3 to 5 days for pain relief without consulting a medical professional.

These instructions establish a rigid framework for the short-term use of the medicine, dictating the minimum time interval between doses (4 hours) and setting a definitive 24-hour limit on the total amount of medicine (1200 mg). The protocol prioritizes the use of the lowest effective dose for the shortest duration necessary to control symptoms, ensuring a standardized approach to self-medication.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies

Phase 3 Trials: Chronic Pain Management

Research included studies that examined the compound in participants with chronic pain, with several Phase 3 trials investigating its activity. These studies aimed to observe the compound’s performance compared to placebo in a large, diverse participant group.

  • One key study reported changes in pain scores over a 12-week period. This investigation focused on adults diagnosed with persistent non-malignant musculoskeletal pain.
  • Another trial examined various dosing schedules to determine their impact on reported outcomes.

Investigating Mechanism of Action

Studies investigated whether the combination of active ingredients affected inflammation. The compound includes two established molecules that researchers hypothesized might exhibit synergistic effects on pain signaling pathways.

  • Laboratory research evaluated how the compound interacted with specific cellular receptors implicated in pain transmission.
  • Research examined the timeline of reported effects in comparison to other compounds.

Safety and Tolerability Data

Phase 2 data included a preliminary assessment of safety parameters in the adult population studied. The primary focus of these early stages was to identify potential adverse events and determine the maximum tolerated dose.

  • Reported adverse events were often characterized as mild and transient in the study reports. Common reports included gastrointestinal upset and transient headache, with all reported effects being monitored throughout the trial periods.

Ongoing Research

Future research will explore the possibility of investigating the compound’s effects in relation to neurological disorders. Researchers are also conducting an open-label extension trial to gather long-term safety data.

  • Study protocols included the evaluation of the compound alongside food intake.
  • The research team is planning further trials to examine effects in different patient groups.

Key Studies & References

  1. Clinical Guideline for the Management of Persistent Non-Malignant Pain (Relevant National Health Service/Society Monograph)
  2. Phase 2 Study Report on Dose Escalation and Safety Profile in Adult Volunteers
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ibuprom Sprint Caps (FAQ)

Q: Is Ibuprom Sprint Caps the same as regular ibuprofen tablets?

A: The core active ingredient, ibuprofen, is the same molecule found in regular ibuprofen tablets. The 'Sprint Caps' use a soft capsule formulation, which holds the active drug in a pre-solubilized liquid form. Official documents describe this unique design as intending to enhance the speed of absorption compared to conventional solid tablets.

Q: How quickly can someone expect the effect to start after taking it?

A: The specialized soft capsule and liquid-fill formulation are designed for rapid release once the medicine is swallowed. Regulatory studies often note that the onset of pain relief usually begins within 30 to 45 minutes of administration. The time it takes to feel the effects can still vary between individuals.

Q: Can this medication affect blood pressure levels?

A: Official safety information indicates that non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may potentially cause the new onset of high blood pressure (hypertension) or worsen existing high blood pressure. Fluid retention and swelling (edema) have also been reported in association with the use of this class of medication. This is a general safety consideration noted in official documents.

Q: Can people with high stomach acid levels use this drug?

A: The official product information specifies that this medicine is contraindicated for individuals with active or a history of recurrent peptic ulcers or gastrointestinal bleeding. Official administration guidelines mention taking the medicine after meals as a condition intended to help minimize stomach discomfort for patients with a sensitive stomach. The official documents outline these risks as part of the overall safety profile.

Q: Does the medicine come in different strength options?

A: For over-the-counter (OTC) use, Ibuprom Sprint Caps are typically available in a single strength containing 200 mg of ibuprofen per soft capsule. The official dosage forms listed in regulatory documents confirm this specific strength for consumer self-medication.

Q: What are the characteristics of the liquid inside the capsule?

A: The active ingredient is dissolved in a specialized liquid fill matrix inside the capsule. This liquid includes various inactive ingredients (excipients), such as polyols or solvents, that work to keep the ibuprofen pre-solubilized. This formulation is key to the product's rapid-release design.

Q: What is the role of the capsule shell in the drug's effect?

A: The soft gelatin shell primarily serves to protect the liquid contents and ensure stable delivery of the medicine. Its crucial role in the drug's effect is that it is designed to dissolve quickly in the stomach. This rapid dissolution allows the pre-dissolved ibuprofen to be released and absorbed into the bloodstream more rapidly than traditional hard-pressed tablets.

Q: Does this medicine contain paracetamol (acetaminophen)?

A: The official product information states that the sole active ingredient in Ibuprom Sprint Caps is ibuprofen. Combination products that include paracetamol (acetaminophen) are distinct medicines and would be listed with both active ingredients on the label.

Q: What is the usual duration of action for Ibuprom Sprint Caps?

A: Official pharmacokinetic studies and product information suggest that the pain-relieving effects of the medicine typically last for approximately four to six hours. This duration of action is reflected by the official administration condition which specifies a minimum interval of four hours between doses.

Q: Is it possible to take Ibuprom Sprint Caps with common allergy medicines?

A: Regulatory documents generally do not list a direct interaction between ibuprofen and common antihistamines (allergy medicines). However, combining any medications always carries a potential for effect. Due to the potential for unforeseen effects, the official guidance often mandates that combinations of medications be reviewed by a healthcare professional.

Q: What is stated about using the drug while breastfeeding?

A: Regulatory guidance often describes ibuprofen as a preferred analgesic option for nursing mothers. Studies show that only a very small amount of the drug is excreted into breast milk. Based on the available evidence, ibuprofen is frequently described in regulatory contexts as compatible with breastfeeding for short-term use at the recommended doses.

Q: Where can I find official, regulatory information about this product?

A: Official, authoritative information about the product is made publicly available through governmental drug databases such as the FDA DailyMed, the EMA, and the MHRA public portals. Consumers can also rely on the Patient Information Leaflet (PIL) or Summary of Product Characteristics (SmPC) that is packaged with the medicine.

Q: Is it normal to feel drowsy after taking this type of medication?

A: Official product documents list somnolence, or drowsiness, as a potential but generally infrequent side effect of ibuprofen. Official guidance states that activities like driving or operating machinery should be avoided if this effect is experienced, in alignment with safety standards.

Q: Is this medication described as being habit-forming?

A: Regulatory authorities do not classify ibuprofen as a controlled substance, and it is not generally associated with physical dependence. However, official warnings caution that the extended and excessive use of any pain reliever can lead to a condition called Medication Overuse Headache.

Q: Does this drug have a risk of interaction with multivitamins?

A: There are no specific documented interactions listed in official regulatory documents between ibuprofen and standard multivitamins. For any combination of a medicine and a supplement, regulatory bodies stipulate that review by a healthcare professional is necessary.

Q: Can I use Ibuprom Sprint Caps if I am scheduled for minor surgery?

A: Ibuprofen is known to affect blood clotting (platelet aggregation), which is an important consideration around surgical procedures. Regulatory guidelines for NSAIDs include stopping the medicine one day before surgery as a measure to minimize potential bleeding risk. The definitive instruction regarding peri-operative use remains the responsibility of the treating physician.

Q: Are there specific food types that are described as interacting with the medicine?

A: Official drug labels and product information do not list specific food types that interact with ibuprofen. The only guidance related to food is the administration instruction to take the medicine with or after food to help reduce the potential risk of stomach irritation.

Q: Is it possible to take this medicine with certain types of herbal supplements?

A: Official documents warn that taking ibuprofen with certain herbal supplements can increase the risk of bleeding. Specifically, there is regulatory guidance cautioning against combining this medicine with any supplements that possess known antiplatelet or anticoagulant (blood-thinning) properties.

Q: Does Ibuprom Sprint Caps interact with medications for diabetes?

A: Regulatory sources indicate that non-steroidal anti-inflammatory drugs (NSAIDs) may impact blood sugar control or interact with kidney function, which can be critical for individuals taking antidiabetic medications. For this reason, official guidance requires that the combination of these medicines be reviewed by a healthcare professional.

Q: Is there official information available in languages other than the local one?

A: In regions like the European Union or Canada, regulatory authorities often require patient information to be translated and provided in all official languages of the region where the product is sold. This ensures that the safety and usage information is accessible to the entire patient population as required by official standards.

Q: Are there any descriptions of rebound headaches associated with this drug?

A: Yes, regulatory and authoritative medical sources include warnings that the frequent or excessive use of simple pain relievers, including NSAIDs like ibuprofen, may lead to a condition called Medication Overuse Headache. This warning emphasizes the need to adhere to the short-term use guidelines described in the product information.

Q: Can someone who is lactose intolerant use this medicine?

A: Official product documentation must provide a complete list of all inactive ingredients (excipients). While soft capsule formulations generally do not contain lactose, regulatory guidance requires that individuals with specific intolerances consult the product's official excipient list for certainty.

Q: What are the official recommendations regarding driving while using this medicine?

A: Official guidance notes that the medicine may potentially cause side effects such as dizziness, somnolence (drowsiness), or visual disturbances. Official safety documents specify that driving or operating heavy machinery must be avoided if these effects are experienced, in accordance with safety standards.

Q: Are there any notable drug-drug interactions with common antidepressants?

A: Yes, official documents specifically address potential drug-drug interactions between ibuprofen and certain antidepressants. Regulatory warnings note that taking the medicine alongside Selective Serotonin Reuptake Inhibitors (SSRIs) is known to increase the risk of serious side effects, particularly the risk of gastrointestinal bleeding.

Advertisements

How should Ibuprom Sprint Caps be stored and disposed of?

Storage & Disposal Profile

The official storage conditions for this medicine require it to be kept at controlled room temperature, typically below 25 C or 30 C, as specified on the label. To maintain its stability and effectiveness, the capsules must be stored in the original container/package to protect them from moisture and light. It is critical to keep the medicine out of the sight and reach of children to prevent accidental ingestion.

Disposal of Unused Medicine

Do not use the medicine past the expiry date shown on the packaging. The preferred method for disposal is using an authorized drug take-back program (e.g., pharmacy kiosk or DEA event). If a take-back program is not available, official guidance states the medicine should be mixed with an undesirable substance (like dirt or used coffee grounds), sealed in a container, and placed in the household trash. Do not flush the capsules down the toilet or pour them down the drain unless specifically instructed by a regulatory authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ibuprom Sprint Caps found in:

A-Z Index: